Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Treatment Strategy Based on Prognostic Groups for Pediatric de Novo Acute Myeloid Leukemia

NCT02848183 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02848183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02848183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Treatment Strategy Based on Prognostic Groups for Pediatric de Novo Acute Myeloid Leukemia
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2016
Completion date
Not reported
Enrollment
350
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric acute myeloid leukemia